Von Hippel-Lindau Protein, Recombinant, Human (vHL)

Von Hippel-Lindau disease(VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet(beta-domain) and a smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).\n\nDescription: \nRecombinant Human VHL beta-domian is a single,non-glycosylated polypeptide chain containing 174aa and has a molecular mass of 19.2kD.\n\nSequence: \nMGSSHHHHHH SSGLVPRGSH MPRRAENWDE AEVGAEEAGV EEYGPEEDGG EESGAEESGPEESGPEELGA EEEMEAGRPR PVLRSVNSRE PSQVIFCNRS PRVVLPVWLN FDGEPQPYPT LPPGTGRRIH SYRGHLWLFR DAGTHDGLLV NQTELFVPSL NVDGQPIFAN ITLP\n\nStorage and Stability: \nMay be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing.. Store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2640-14

Size

10ug

Form

Supplied as a liquid in PBS, 2mM EDTA, pH 7.4.

Purity

(same/more than) 95% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (VHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood 2006 Jun 29. 2. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006 May 5;22(3):395-405. 3. Calpain mediates a von Hippel-Lindau protein-independent destruction of hypoxia-inducible factor-1alpha. Mol Biol Cell 2006 Apr;17(4):1549-58. 4. Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1alpha and the von Hippel-Lindau protein. J Physiol 2006 Mar 1;571(Pt 2):349-59. 5. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 2005 Dec 9;338(1):627-38. 6. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol 2005 Sep;25(17):7546-56